Modality
Small Molecule
MOA
CDK4/6i
Target
Aβ
Pathway
Fibrosis
Parkinson's
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
~Sep 2017
→ ~Dec 2018
Phase 3
Mar 2019
→ May 2031
Phase 3Current
NCT08186560
2,249 pts·Parkinson's
2021-01→2029-04·Completed
NCT06751639
1,082 pts·Parkinson's
2020-06→2025-12·Not yet recruiting
NCT03113410
196 pts·Parkinson's
2019-03→2031-05·Not yet recruiting
3,527 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-12-104mo agoPh3 Readout· Parkinson's
2029-04-183.0y awayPh3 Readout· Parkinson's
2031-05-135.1y awayPh3 Readout· Parkinson's
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Not yet…
P3
Not yet…
P3
Complet…
Catalysts
Ph3 Readout
2025-12-10 · 4mo ago
Parkinson's
Ph3 Readout
2029-04-18 · 3.0y away
Parkinson's
Ph3 Readout
2031-05-13 · 5.1y away
Parkinson's
CompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08186560 | Phase 3 | Parkinson's | Completed | 2249 | PASI75 |
| NCT06751639 | Phase 3 | Parkinson's | Not yet recr... | 1082 | CfB |
| NCT03113410 | Phase 3 | Parkinson's | Not yet recr... | 196 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ |